Gelteq Appoints New Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

Gelteq Limited recently announced the appointment of Dr. Paul Wynne as its Chief Scientific Officer (CSO).

Gelteq co-founder and CEO Nathan Givoni said “We believe Dr. Wynne’s distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq’s product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne’s pedigree aligns with Gelteq’s mission to enhance health and wellness through our novel ingestible gel technology. We look forward to further strengthening our senior management team as we continue to execute a strategic plan to build long-term value for all of our stakeholders.”

Dr. Wynne will oversee the product and formulation strategies and the growth of Gelteq’s scientific team and various business verticals. He will assist with Gelteq’s intellectual property portfolio, academic partnerships, gel formulations, and distribution channels, and will work closely with manufacturing and supply side partners.

Dr. Wynne commented “I am honored to join Gelteq at such an exciting inflection point for the Company and the industry. I look forward to guiding the Company’s efforts to fully harness the potential of our ingestible gel technology across a myriad of market applications to meet the evolving needs of consumers and patients around the world.”

Dr. Wynne has over 35 years of experience in the disciplines of analytical chemistry, the design and manufacture of advanced materials, drug metabolism, pharmaceutical formulation, drug delivery and forensic toxicology. Prior to joining Gelteq, he was the Manager of the Medicines Manufacturing Innovation Centre at Monash University in Melbourne for eight years, which works to strengthen the pharmaceutical and allied manufacturing sector in Australia for domestic and International clients. Monash University is ranked No. 2 in the world in pharmacy and pharmaceutical science by the QS World University Rankings by Subject 2024: Pharmacy & Pharmacology. Dr. Wynne is also the author of over 80 peer reviewed papers, book chapters, and patents, and more than 120 lectures, presentations and industry technical articles. He holds a Bachelor of Applied Science (Applied Chemistry), Master of Applied Science (Organic Photochemistry), and a Doctor of Philosophy (Chemistry and Toxicology) from RMIT University.

Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a global biotechnology company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition. The company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit www.gelteq.com.